🇺🇸 FDA
Patent

US 8470312

Abrogating proinflammatory cytokine production during oncolytic reovirus therapy

granted A61KA61K31/282A61K31/555

Quick answer

US patent 8470312 (Abrogating proinflammatory cytokine production during oncolytic reovirus therapy) held by ONCOLYTICS BIOTECH INC. expires Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ONCOLYTICS BIOTECH INC.
Grant date
Tue Jun 25 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/282, A61K31/555, A61K33/243, A61K35/765